RadCommonsuma iniciativa da Laudos.AI
BCLC · Fígado
Sistemas/Fígado

BCLC Barcelona Clinic Liver Cancer staging

vigente

Stages hepatocellular carcinoma by tumor burden, liver function, and performance status to guide treatment and prognosis.

Índice de referência, não é suporte à decisão clínica. O RadCommons apresenta conteúdo de referência reescrito a partir de critérios publicados e com link para a fonte primária. Confira sempre a publicação primária vigente. Não é um dispositivo médico nem substitui o julgamento clínico. O radiologista responsável pelo laudo permanece o autor e o responsável.
Escala de categorias
0ABCD

As figuras e tabelas estão na fonte primária. Abrir a fonte. O RadCommons reescreve e cita, não reproduz figuras protegidas por direitos autorais.

Procedência e vigência

Órgão emissor
Barcelona Clinic Liver Cancer group
Versão
2022
Ano
2022
Família
algoritmo
Tipo de lógica
flat
Modalidade
CT, MRI, US
Fonte primária
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update · doi:10.1016/j.jhep.2021.11.018
Última verificação
2026-06-22
Última checagem
2026-06-22

Lógica de decisão

Forma estruturada (flat). Uma futura calculadora a lê; as categorias abaixo são a superfície legível.

Mostrar a lógica estruturada (JSON)
{
  "categories": [
    "0",
    "A",
    "B",
    "C",
    "D"
  ]
}

Categorias num relance

Cat.SignificadoCondutaRiscoFonte
0
Stage 0, very early
Very early stage: a single tumor up to 2 cm, no vascular invasion or extrahepatic spread; preserved liver function (Child-Pugh A) and ECOG performance status 0.		Ablation (radiofrequency or microwave) is the usual first option; resection where feasible, and liver transplantation in selected candidates.Best prognosis: median survival exceeds 5 years.
okfonte
PMC8866082 (Reig et al., J Hepatol 2022), BCLC 2022 algorithm/summary and treatment-strategy section; criteria corroborated by NCBI Bookshelf NBK569796 BCLC staging table (single <=2 cm, CP A, PS 0).
A
Stage A, early
Early stage: a solitary tumor of any size, or up to 3 nodules each up to 3 cm, with no macrovascular invasion or extrahepatic spread; preserved liver function (Child-Pugh A-B) and ECOG performance status 0.		Curative options: resection (preferred without clinically significant portal hypertension), ablation for tumors up to 3 cm, or transplant when high recurrence-risk pathology is present.Favorable prognosis: median survival exceeds 5 years.
okfonte
PMC8866082, BCLC 2022 algorithm and treatment-strategy section; criteria corroborated by NBK569796 table (single, or <=3 nodules <=3 cm, CP A-B, PS 0).
B
Stage B, intermediate
Intermediate stage: multinodular hepatocellular carcinoma exceeding early-stage limits, without macrovascular invasion or extrahepatic spread; preserved liver function and ECOG performance status 0.		Transarterial chemoembolization is the reference treatment when liver function is preserved; transplant under extended criteria for selected patients, and systemic therapy for extensive or diffuse bilobar disease unsuitable for chemoembolization.Median survival around 2.5 years.
okfonte
PMC8866082, BCLC 2022 algorithm and treatment-strategy section; criteria corroborated by NBK569796 table (multinodular, CP A-B, PS 0).
C
Stage C, advanced
Advanced stage: macrovascular (portal) invasion and/or extrahepatic spread; preserved or compensated liver function (Child-Pugh A-B) and ECOG performance status 1-2.		First-line systemic therapy: atezolizumab plus bevacizumab is the first choice; tremelimumab plus durvalumab, sorafenib, or lenvatinib are alternatives.Median survival around 2 years.
okfonte
PMC8866082, systemic-therapy section; criteria corroborated by NBK569796 table (vascular invasion or extrahepatic spread, CP A-B, PS 1-2).
D
Stage D, terminal
Terminal stage: end-stage liver function (Child-Pugh C, not transplant-eligible) and/or ECOG performance status 3-4 or major cancer-related symptoms; any tumor burden.		Best supportive and symptomatic care with palliative-care coordination.Poor prognosis: median survival around 3 months.
okfonte
PMC8866082, treatment-strategy section; criteria corroborated by NBK569796 table (any tumor, CP C, PS 3-4).

Referências cruzadas

fronteira compartilhadaCouinaud. Couinaud liver segmentationBCLC stages HCC for treatment planning; Couinaud localizes the tumor for resection planning.

Histórico de versões

DataEventoDetalheSituação
2022-01-01revisedBCLC strategy 2022 update published in the Journal of Hepatology.confirmado
Quickstart da APIGET /api/v1/systems/bclcaberto
curl -s "https://radcommons.laudos.ai/api/v1/systems/bclc"
Ver documentação completa →